Meeting
2022 ASCO Annual Meeting
Effect of durvalumab in patients with unresectable stage 3 non–small cell lung cancer post-chemoradiotherapy.
Authors
Aswani Thurlapati
Department of Internal Medicine, LSU Health Science Center, Shreveport, LA
Aswani Thurlapati , Lovekirat Singh Dhaliwal , Sumasri Chennapragada , Pranavteja Gutta , Diana Song , Deepika Ralla , Jill Comeau , Runhua Shi , Kavitha Beedupalli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8550)
DOI
10.1200/JCO.2022.40.16_suppl.8550
Abstract #
8550
Poster Bd #
177
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).
First Author: Mustafa Özgüroğlu
Poster
2021 ASCO Annual Meeting
Elderly patients with unresectable stage 3 NSCLC treated with definitive chemoradiation with or without durvalumab: Safety and outcomes.
First Author: Malcolm Isaiah Ryan
Poster
2019 ASCO Annual Meeting
First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.
First Author: David Planchard
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
The prognostic significance of PDL1 expression in locally advanced non-small-cell lung cancer (LA-NSCLC) treated with definitive intent.
First Author: Devarati Mitra